| Literature DB >> 35807414 |
Gredson Keiff Souza1, André Gallo2, Luiza Hauser Novicki2, Heitor Rodrigues Neto2, Eneida de Paula3, Anita Jocelyne Marsaioli1, Luis Fernando Cabeça2.
Abstract
The drugs delivery system in the treatment of diseases has advantages such as reduced toxicity, increased availability of the drug, etc. Therefore, studies of the supramolecular interactions between local anesthetics (LAs) butamben (BTB) or ropivacaine (RVC) complexed with 2-hydroxypropyl-β-cyclodextrin (HP-βCD) and carried in Stealth liposomal (SL) are performed. 1H-NMR nuclear magnetic resonance (DOSY and STD) were used as the main tools. The displacements observed in the 1H-NMR presented the complexion between LAs and HP-βCD. The diffusion coefficients of free BTB and RVC were 7.70 × 10-10 m2 s-1 and 4.07 × 10-10 m2 s-1, and in the complex with HP-βCD were 1.90 × 10-10 m2 s-1 and 3.64 × 10-10 m2 s-1, respectively, which indicate a strong interaction between the BTB molecule and HP-βCD (98.3% molar fraction and Ka = 72.279 L/mol). With STD-NMR, the encapsulation of the BTB/HP-βCD and RVC/HP-βCD in SL vesicles was proven. Beyond the saturation transfer to the LAs, there is the magnetization transfer to the hydrogens of HP-βCD. BTB and RVC have already been studied in normal liposome systems; however, little is known of their behavior in SL.Entities:
Keywords: 1H-NMR; NMR-STD; butamben; ropivacaine; stealth liposomes
Mesh:
Substances:
Year: 2022 PMID: 35807414 PMCID: PMC9267999 DOI: 10.3390/molecules27134170
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1(a) BTB Solubility in HP-βCD (slope = 0.3479, R2 = 0.99977); (b) RVC Solubility Graphic In HP-βCD (slope = 0.175, R2 = 0.9994). Determined at room temperature (n = 3).
Figure 2Structures of the molecules of (a) RVC; (b) BTB; (c,d) HP-βCD.
Attribution and chemical shift of BTB 1H and RVC 1H in the binary and ternary complexes.
|
|
|
|
|
|
|
|
|
| 2 | 6.76 | - | - | 6.69 | −0.07 | 6.67 | −0.02 |
| 3 | 7.78 | - | - | 7.66 | −0.12 | 7.66 | 0.00 |
| 5 | 7.78 | - | - | 7.66 | −0.12 | 7.66 | 0.00 |
| 6 | 6.76 | - | - | 6.69 | −0.07 | 6.67 | −0.02 |
| 7 | 4.23 | - | - | 4.26 | 0.03 | - | - |
| 8 | 1.66 | - | - | 1.68 | 0.02 | 1.68 | 0.00 |
| 9 | 1.36 | - | - | 1.39 | 0.03 | 1.38 | 0.01 |
| 10 | 0.87 | - | - | 0.91 | 0.04 | 0.92 | 0.01 |
|
|
|
|
|
|
|
|
|
| 1,2,3 Aromatic | 7.14 | 7.14 | 0.00 | 7.15 | 0.01 | 7.14 | - |
| 7 | 4.12 | 4.10 | −0.02 | 4.10 | −0.02 | - | - |
| 8 e | 2.37 | 2.37 | 0.00 | 2.37 | 0 | - | - |
| 11 e | 3.67 | - | - | - | - | - | - |
| 12, 11 a | 3.08 | 3.30 | 0.22 | 3.06 | −0.02 | 3.17 | 0.09 |
| 15, 16 | 2.12 | 2.12 | 0.00 | 2.14 | 0.02 | 2.14 | 0.02 |
| 14 | 0.89 | 0.89 | 0.89 | 0.9 | −0.01 | 0.90 | 0.01 |
a axial hydrogen; e equatorial hydrogen; * concentration = 10 mM
Figure 3(a) Alternative topology for the BTB/HP-βCD and (b) RVC/HP-βCD complex.
Diffusion coefficients (D) of LA (BTB, RVC), HP-βCD and LA/HP- βCD, LA/HP-βCD/SL constant association (Ka) and molar fraction (fx).
| Complex | Compounds | Molar Fraction of | ||
|---|---|---|---|---|
| RVC | 4.07 ± 0.40 | |||
| SL | 0.32 ± 0.17 | |||
| HP-βCD | 2.04 ± 0.03 | |||
| RVC/SL | 3.38 ± 0.05 | 18 | 28 | |
| RVC/HP-βCD | 3.64 ± 0.02 | 22 | 37 | |
| RVC/HP-βCD/SL | 3.14 ± 0.12 | 25 | 44 | |
| BTB | 7.70 ± 0.12 | |||
| BTB/HP-βCD | 1.90 ± 0.25 | 98.3 | 72,279 |
RVC—Ropivacaine; BTB—Butamben; SL—Stealth liposomes; D—Diffusion Coefficients; HP-βCD—2-Hydroxypropyl-β-cyclodextrin.
Figure 4(A) 1H NMR spectrum (400 MHz, D2O/residual H2O reference at 4.7 ppm) of the BTB/HP-βCD/SL complex (50 mmol L−1); (B) control spectrum (radiating at 30 ppm); (C) STD spectrum (radiating at −0.5 ppm). Total saturation time 2.55 s.
Data obtained in the STD experiments.
| Frequency (ppm) | Area STD | Area Outside Resonance | Map STD Standardized |
|---|---|---|---|
| H2 e 6 BTB = 6.67 | 0.0242 | 0.8989 | 97.4% |
| H3 e 5 BTB = 7.66 | 0.0234 | 0.8575 | 97.3% |
| H9 BTB = 1.38 | 0.1550 | 1.0000 | 84.6% |
| H8 BTB = 1.68 | 0.1639 | 1.3054 | 87.5% |
| H14 RVC = 0.90 | 0.0035 | 1.3873 | 34% |
| H1, H2, H3 RVC = 7.14 | 0.0074 | 1.0000 | 100% |
| H15, H16 RVC = 2.14 | 0.0049 | 1.8851 | 35% |
Figure 5(A) STD spectrum (radiating at −0.5 ppm); (B) control spectrum (radiating at 30 ppm); (C) 1H NMR spectrum (400 MHz, D2O/residual H2O reference at 4.7 ppm) of RVC/HP-βCD/SL complex [50 mmol L−1]. Total saturation time 2.55 s.
Diameter of the vesicle liposome, polydispersity value and zeta potential.
| Particles | Size (nm) | IP | PZ (mV) |
|---|---|---|---|
| SL | 202 ± 1.02 | 0.30 | −22.0 ± 0.90 |
| BTB/SL | 200 ± 0.91 | 0.40 | −23.5 ± 0.63 |
| BTB/HP-βCD/SL | 229 ± 0.91 | 0.36 | −25.1 ± 0.26 |
| RVC/SL | 200 ± 0.88 | 0.40 | −22.5 ± 0.60 |
| RVC/HP-βCD/SL | 285 ± 0.91 | 0.40 | −25.1 ± 0.26 |
SL—Stealth Liposome; BTB/SL—Butamben and Stealth Liposomes; BTB/SL/HP-βCD:BTB—Stealth Liposomes, 2-Hydroxypropyl-β-cyclodextrin and butamben; RVC/SL–Ropivacaine and Stealth Liposome; SL/HP-βCD/RVC Stealth liposomes, 2-Hydroxypropyl-β-cyclodextrin and ropivacaine.